Skip to content
Screener

Pre-Tax Income at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$70.99M+37.3%
Viatris logo
ViatrisVTRS
-$64M+70.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$52.84M-34.5%
ALN
Alnylam PharmaceuticalsALNY
$177.81M+603%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.57M+205%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$48.79M+120%

Segments

By segment

See full
Rare Disease and Brands$52.35M+77.7%
Generics and Other$36.49M-4.4%

Other financials

Income statement

See full
Revenue$266.0M+25.9%
Gross profit$165.9M+21.3%
Operating income$40.5M+191%
Net income$24.7M+189%
EPS (diluted)$1.05+192%

Balance sheet

See full
Cash & equivalents$360.2M+65.4%
Total debt$301.5M-4.2%
Total equity$597.2M+36.7%
Total assets$1.5B+11.3%

Cash flow

See full
Operating cash flow$56.7M-25.3%
CapEx$3.1M-23.9%
Free cash flow$53.6M-25.3%

Valuation

See full
Market cap$1.88B+25.6%
Enterprise value$1.82B+14.3%
P/E17.3×
P/S1.9×-0.1×

Profitability

See full
Gross margin60.4%-0.7pp
Operating margin15.4%
Net margin11.1%+10.0pp
FCF margin17.7%+0.9pp

Returns & leverage

See full
Return on equity21%+19.1pp
Debt / equity0.5×-0.2×
Current ratio2.9×+0.4×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 7:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001023024-26-000069
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Unrealized gain (loss) on investment in equity securities7413326,494(589)
Interest expense, net(3,636)(5,438)(7,405)(10,922)
Other (expense) income, net(468)1,739(1,119)1,937
Income Before Income Tax Expense37,09710,52577,31830,512
Income tax expense12,3861,97623,1156,282
Net Income$24,711$8,549$54,203$24,230
Dividends on Series A Convertible Preferred Stock(407)(813)
Net Income Available to Common Shareholders$24,711$8,142$54,203$23,417

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is ANI Pharmaceuticals's pre-tax income?
ANI Pharmaceuticals (ANIP) reported pre-tax income of $37.1M in Q2 2026.
How has ANI Pharmaceuticals's pre-tax income changed year-over-year?
ANI Pharmaceuticals's pre-tax income increased by 252.5% year-over-year, from $10.53M to $37.1M.
What is the long-term trend for ANI Pharmaceuticals's pre-tax income?
Over 4 years (2021 to 2025), ANI Pharmaceuticals's pre-tax income has grown at a 14.3% compound annual growth rate (CAGR), from -$56.06M to $95.79M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about ANI Pharmaceuticals's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude